05/08/2020 8:09 am Welcome to isteroids.com - BLOG

Tuesday 27, Dec 2011

  Steroid use substantially reduced by canakinumab

Posted By
Pin it Share on Tumblr

Novartis will be presenting positive phase III data results on November 9 from ACZ885, a fully human monoclonal antibody that inhibits IL-1 beta at the American College of Rheumatology‘s (ACR) Annual Scientific Meeting in Chicago, US.

It was suggested by the study that 45 per cent of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001).

“These data demonstrate the significant benefits that ACZ885 may provide this young population, both in steroid reduction and in extending the period these children can live free from SJIA flares,” said David Epstein, Head of the Pharmaceuticals Division of Novartis. “Novartis is committed to helping improve the health of patients with SJIA and other inflammatory diseases, which is why we are delighted to be sharing these results.”

Tuesday 02, Nov 2010

  Large corticosteroid doses and asthma exacerbation

Posted By
Pin it Share on Tumblr

Large corticosteroid doses and asthma exacerbationAccording to a work published in The Cochrane Library this month, there is no evidence to suggest that increasing the dose of inhaled corticosteroids at the onset of an asthma exacerbation as part of a patient-initiated action plan minimizes the need for rescue oral corticosteroids.

Lead researcher Francine Ducharme, who works at the University of Montreal, Canada remarked that keeping to a constant dose has the potential of reinforcing the effectiveness of taking daily inhaled corticosteroids, not only during exacerbations and/or encourage the search for more effective strategies.

ucharme also said that more pediatric studies are needed to guide treatment of exacerbations and the best approach would be all about preventing an exacerbation by ensuring regular use of inhaled corticosteroids.

Monday 19, Apr 2010

  Inhaled steroids beneficial for patients with cystic fibrosis

Posted By
Pin it Share on Tumblr

Inhaled steroids beneficial for patients with cystic fibrosisAccording to a finding presented in an issue of the American Journal of Respiratory and Critical Care Medicine and published by the American Thoracic Society, there is no difference in terms of benefits when comparisons are made between cystic fibrosis (CF) patients on inhaled corticosteroids and those who didn’t use inhaled steroids for six months.

Ian M. Balfour-Lynn, M.D., F.R.C.P., of the Department of Pediatric Respiratory Medicine at Royal Brompton Hospital in London, and six associates concluded that it is safe for the patients to stop using corticosteroids for lowering their drug burden, save money, and minimize adverse side effects.

Dr. Balfour-Lynn remarked that replacing the corticosteroids with a placebo was safe as it did not led to a significant increase in lung-related adverse effects leading to withdrawal from the study, nor an increased need for oral corticosteroids.

Wednesday 12, Aug 2009

  New Research on use of Chronic Corticosteroid

Posted By
Pin it Share on Tumblr

New Research on use of Chronic CorticosteroidNew findings have been revealed with regard to use of chronic corticosteroid at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Seattle.

According to Rebecca Green, M.D., Ph.D., Assistant Professor, Pediatric Endocrinology and Diabetes, Washington University School of Medicine in St. Louis, Mo., corticosteroids have been considered to be miracle drugs for many ailments when it comes to controlling symptoms where other medications failed to deliver any good results.

As per Dr. Kelly, Professor Emeritus Of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, N.M., the use of inhaled corticosteroids has the potential for minimizing bone mineral growth in male children who are progressing through the stage of puberty, but the associated risk is more likely to be outweigh by an ability to minimize the quantity of oral corticosteroids used in these children.

Wednesday 01, Jul 2009

  Oral Corticosteroids – Effective In Treating Polymyalgia Rheumatica

Posted By
Pin it Share on Tumblr

Oral Corticosteroids – Effective In Treating Polymyalgia RheumaticaPolymyalgia rheumatica (PMR) is an inflammatory disorder that causes widespread muscle pains and stiffness, primarily in the neck, shoulders, upper arms, thighs and hips. Usually, this condition occurs to people over the age of 50. What trigger the causes of this condition is still unknown, although some factors causing this are considered such as problem with the immune system, genetic and environmental factors; and aging.

Polymyalgia rheumatica usually goes away on its own in a year or two. But you don’t have to endure polymyalgia rheumatica for months or years. Medications and self-care measures can improve your symptoms. Among the effective treatments for the disorder are steroids and anti-inflammatory medications.

The common polymyalgia rheumatica treatment is a low, daily dose of an oral corticosteroid drug such as prednisone. Relief should be immediate. But if you don’t feel any relief using oral corticosteroids, it is likely that you don’t actually have a polymyalgia rheumatic. When this happens, seek professional medical advice.